BioCryst Pharmaceuticals, Inc. $BCRX Stock: GW&K Investment Management LLC Increases Position

GW&K Investment Management LLC grew its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 6.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,361,960 shares of the biotechnology company’s stock after purchasing an additional 190,847 shares during the period. GW&K Investment Management LLC’s holdings in BioCryst Pharmaceuticals were worth $28,006,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Nykredit A S acquired a new position in BioCryst Pharmaceuticals in the 2nd quarter valued at $27,000. Winthrop Capital Management LLC purchased a new position in BioCryst Pharmaceuticals during the 3rd quarter worth $25,000. IFP Advisors Inc raised its position in BioCryst Pharmaceuticals by 2,515.3% during the 2nd quarter. IFP Advisors Inc now owns 3,243 shares of the biotechnology company’s stock worth $32,000 after buying an additional 3,119 shares during the last quarter. Allworth Financial LP acquired a new stake in shares of BioCryst Pharmaceuticals in the 2nd quarter worth $52,000. Finally, Pallas Capital Advisors LLC acquired a new stake in shares of BioCryst Pharmaceuticals in the 2nd quarter worth $101,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ BCRX opened at $7.22 on Friday. BioCryst Pharmaceuticals, Inc. has a one year low of $6.23 and a one year high of $11.22. The firm has a market capitalization of $1.86 billion, a P/E ratio of -5.09 and a beta of 0.55. The company’s fifty day moving average is $8.08 and its two-hundred day moving average is $8.79.

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. BioCryst Pharmaceuticals had a negative net margin of 37.40% and a negative return on equity of 92.91%. The business had revenue of $180.29 million during the quarter, compared to the consensus estimate of $165.67 million. During the same quarter last year, the firm posted $0.06 EPS. The business’s revenue was up 13.1% compared to the same quarter last year. On average, sell-side analysts forecast that BioCryst Pharmaceuticals, Inc. will post -2.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BCRX has been the topic of several analyst reports. JPMorgan Chase & Co. lifted their target price on shares of BioCryst Pharmaceuticals from $12.00 to $13.00 and gave the company a “neutral” rating in a report on Wednesday, September 30th. Wedbush cut their price target on shares of BioCryst Pharmaceuticals from $18.00 to $17.00 and set an “outperform” rating for the company in a report on Thursday, November 5th. Weiss Ratings downgraded shares of BioCryst Pharmaceuticals from a “hold (c)” rating to a “sell (d-)” rating in a research report on Tuesday, September 22nd. Wall Street Zen lowered BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Saturday, November 7th. Finally, Royal Bank Of Canada cut BioCryst Pharmaceuticals from an “outperform” rating to a “sector perform” rating and dropped their target price for the stock from $13.00 to $11.00 in a research report on Thursday, September 10th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $20.38.

View Our Latest Stock Report on BCRX

About BioCryst Pharmaceuticals

(Free Report)

BioCryst Pharmaceuticals is a biotechnology company that discovers, develops and commercializes medicines for rare diseases. Founded in 1986, the company is headquartered in Durham, North Carolina, and focuses on small-molecule treatments. Its principal product is ORLADEYO (berotralstat), an oral medicine for preventing attacks of hereditary angioedema, a rare condition that causes episodes of swelling. BioCryst also develops medicines for rare diseases, including candidates targeting hereditary angioedema and complement-mediated disorders.

Featured Articles

Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report).

Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.